ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Tuesday, November 9, 2021

8:30AM-10:30AM: Abstract Number: 1485

Glycosphingolipids: Potential Urine Biomarkers of Therapeutic Response in Lupus Nephritis

SLE – Etiology & Pathogenesis Poster (1480–1506)

8:30AM-10:30AM: Abstract Number: 1808

Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial

Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Abstract Number: 1600

Has the COVID 19 Pandemic Impacted the Management of Chronic Musculoskeletal Pain?

Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

8:30AM-10:30AM: Abstract Number: 1605

Health Related Quality of Life in Rheumatology Outpatients with COVID-19 from New York City over the Course of the Pandemic

Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

8:30AM-10:30AM: Abstract Number: 1852

Healthcare Utilization and Economic Burden in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

8:30AM-10:30AM: Abstract Number: 1539

High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1725

Higher Prevalence of Aspirin Use with a Specific Educational Tool in SLE Pregnancies: Preliminary Results

Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

8:30AM-10:30AM: Abstract Number: 1839

Hispanic Patients with Systemic Sclerosis Have More Severe Disease and Higher Mortality: A Longitudinal Cohort Study

Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

8:30AM-10:30AM: Abstract Number: 1762

Hydroxychloroquine Alone Does Not Increase QTc in the Absence of Other QT-prolonging Medications

SLE – Treatment Poster (1732–1772)

8:30AM-10:30AM: Abstract Number: 1753

Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors

SLE – Treatment Poster (1732–1772)

8:30AM-10:30AM: Abstract Number: 1875

Hyoscine Butylbromide Inhibits Neutrophil Cell Death Induction by Cocaine-levamisole. a Proof of Concept for the Management of Vasculopathy Induced by Cocaine-Levamisole

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

8:30AM-10:30AM: Abstract Number: 1566

Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

8:30AM-10:30AM: Abstract Number: 1489

Identification of Mitochondrial Antigens Targeted by Autoantibodies in Systemic Lupus Erythematosus (SLE)

SLE – Etiology & Pathogenesis Poster (1480–1506)

8:30AM-10:30AM: Abstract Number: 1650

Identifying Trajectories and Endotypes in the Evolution of Pre-Rheumatoid Arthritis with Autoantibody Testing and Artificial Adaptive System Analysis

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

8:30AM-10:30AM: Abstract Number: 1499

Imbalance Between T Follicular Cells and T Regulatory Cells Involved in High Fat-Diet Associated Lupus Development in MRL/lpr Mice

SLE – Etiology & Pathogenesis Poster (1480–1506)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].